Top news of the week: 03.08.2022.
Biotech’s Prospects Transition from Hero to Zero and – Maybe – Back Again
The biotech industry is facing what some consider the worst times since its inception. Several market analysts recently shared their thoughts.
Ipsen Invests Potential $1.6B to Turbo-Charge Marengo's Path to the Clinic
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
Biopharma 101: analysis of protein therapeutics
Date: August 11, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 7:00pm (CEST) Proteins have long been recognized as novel molecules due to their broad therapeutic applications. However, with the nu
Beyond Biotech podcast 7: World Hepatitis Day
This week's podcast features three interviews related to hepatitis. Our guests are Ahmed Elsharkawy, Ziv Ben-Ari, and James McIlroy.
Investor's Corner: Q2 Pharma and Biotech Insights for Investors
As the second financial quarter of the year comes to a close, pharma and biotech companies large and small are releasing their financial results. For more information on the top-earning ...
Lepu Biopharma anti-PD-1 antibody receives China’s nod for solid tumors
Lepu Biopharma Co. Ltd. has been given conditional approval by China’s NMPA for its anti-PD-1 monoclonal antibody, Puyouheng (pucotenlimab injection), based on data from a phase II study. ...
Taiwan's CancerFree Biotech Ltd Develops World's First Commercial Personalized Cancer Cell Profile
Taiwan's CancerFree Biotech Ltd Develops World's First Commercial Personalized Cancer Cell Profile - read this article along with other careers information, tips and advice on BioSpace
With Some Help Small Canadian Biotech Could Challenge Roche's Hold in Stroke Treatment
NervGen showed that its proprietary drug NVG-291-R could repair the nervous system after a stroke—even when it was given up to seven days after the episode.